Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 6/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5041304 | 0.89 | RAB9A (0.38) | RAB9ASMN1; SMN2HTTNPC1POLB | |
| SCHEMBL5038310 | 0.88 | SMN1; SMN2 (0.37) | RAB9ASMN1; SMN2HTTNPC1POLB | |
| SCHEMBL14278707 | 0.88 | SMN1; SMN2 (0.37) | RAB9ASMN1; SMN2HTTNPC1POLB | |
| SCHEMBL14278746 | 0.77 | SMN1; SMN2 (0.44) | RAB9ASMN1; SMN2HTTNPC1POLB | |
| SCHEMBL5043490 | 0.77 | PLA2G7 (0.37) | RAB9ASMN1; SMN2HTTNPC1POLB | |
| SCHEMBL5041467 | 0.72 | CYP1A2 (0.38) | SMN1; SMN2POLBMEN1KMT2AALDH1A1 | |
| SCHEMBL5033957 | 0.71 | ALDH1A1 (0.38) | RAB9ASMN1; SMN2NPC1POLBMEN1 | |
| SCHEMBL5042461 | 0.71 | CYP1A2 (0.47) | RAB9ASMN1; SMN2NPC1POLBMEN1 | |
| SCHEMBL5043357 | 0.70 | ALDH1A1 (0.36) | RAB9ASMN1; SMN2NPC1POLBMEN1 | |
| SCHEMBL5047754 | 0.68 | KCNN4 (0.39) | RAB9ASMN1; SMN2HTTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1660487-B1 | PYRROLE COMPOSITIONS USEFUL AS INHIBITORS OF C-MET | VERTEX PHARMA (US) | 2008-03-19 | — | — | EP | disclosed |
| EP-1660487-B1 | PYRROLE COMPOSITIONS USEFUL AS INHIBITORS OF C-MET | VERTEX PHARMA (US) | 2008-03-19 | — | — | EP | disclosed |
| US-7314885-B2 | Pyrrole compounds useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-01-01 | — | — | US | disclosed |
| US-7314885-B2 | Pyrrole compounds useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-01-01 | — | — | US | disclosed |
| US-7314885-B2 | Pyrrole compounds useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-01-01 | — | — | US | disclosed |
| US-20060173055-A1 | (4-(4-(2,3-difluorophenyl)-4H-1,2,4-triazol-3-yl)-1H-pyrrol-2-yl)(2H-pyrrol-1(5H)-yl)methanone; anticarcinogenic, antiproliferative and antimetastasis agent; inhibitors of c-Met protein kinase | VERTEX PHARMACEUTICALS INCORPORATED | 2006-08-03 | — | — | US | disclosed |
| EP-1660487-A1 | PYRROLE COMPOSITIONS USEFUL AS INHIBITORS OF C-MET | Vertex Pharmaceuticals Incorporated (US) | 2006-05-31 | — | — | EP | disclosed |
| US-20050101650-A1 | Pyrrole compositions useful as inhibitors of c-Met | VERTEX PHARMACEUTICALS INCORPORATED | 2005-05-12 | — | — | US | disclosed |
| WO-2005016920-A1 | PYRROLE COMPOSITIONS USEFUL AS INHIBITORS OF C-MET | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101650-A1 | Pyrrole compositions useful as inhibitors of c-Met | MET, PRKCH, DMPK | RAB9A 2600/4885SMN1; SMN2 2391/4885HTT 1414/4885 |
| US-20060173055-A1 | (4-(4-(2,3-difluorophenyl)-4H-1,2,4-triazol-3-yl)-1H-pyrrol-2-yl)(2H-pyrrol-1(5H)-yl)methanone; anticarcinogenic, antiproliferative and antimetastasis agent; inhibitors of c-Met protein kinase | MET, DMPK, CDK4 | RAB9A 3397/4885SMN1; SMN2 3423/4885HTT 3031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.